Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways

Y Sun, Yuhao Liu, Wei He, Chao Wang, Jennifer Tickner, Vincent Kuek, Chi Zhou, Haibin Wang, Xuting Zou, Zhinan Hong, Fan Yang, Min Shao, Leilei Chen, Jiake Xu

Research output: Contribution to journalArticle

Abstract

Osteoporosis is a form of osteolytic disease caused by an imbalance in bone homeostasis, with reductions in osteoblast bone formation, and augmented osteoclast formation and resorption resulting in reduced bone mass. Cajaninstilbene acid (CSA) is a natural compound derived from pigeon pea leaves. CSA possesses beneficial properties as an anti-inflammatory, antibacterial, antihepatitis, and anticancer agent; however, its potential to modulate bone homeostasis and osteoporosis has not been studied. We observed that CSA has the ability to suppress RANKL-mediated osteoclastogenesis, osteoclast marker gene expression, and bone resorption in a dose-dependent manner. Mechanistically, it was revealed that CSA attenuates RANKL-activated NF-κB and nuclear factor of activated T-cell pathways and inhibited phosphorylation of key signaling mediators c-Fos, V-ATPase-d2, and ERK. Moreover, in osteoclasts, CSA blocked RANKL-induced ROS activity as well as calcium oscillations. We further evaluated the therapeutic effect of CSA in a preclinical mouse model and showed that in vivo treatment of ovariectomized C57BL/6 mice with CSA protects the mice from osteoporotic bone loss. Thus, this study demonstrates that osteolytic bone diseases can potentially be treated by CSA.

Original languageEnglish
Pages (from-to)11792-11804
Number of pages13
JournalJournal of Cellular Physiology
Volume234
Issue number7
DOIs
Publication statusPublished - 1 Jul 2019

Fingerprint

Osteoclasts
Osteoporosis
Bone
Bone and Bones
Osteogenesis
Homeostasis
NFATC Transcription Factors
Phosphorylation
Calcium Signaling
3-hydroxy-4-prenyl-5-methoxystilbene-2-carboxylic acid
Bone Diseases
Osteoblasts
Peas
Columbidae
Therapeutic Uses
Bone Resorption
Inbred C57BL Mouse
Gene expression
Antineoplastic Agents
Adenosine Triphosphatases

Cite this

Sun, Y ; Liu, Yuhao ; He, Wei ; Wang, Chao ; Tickner, Jennifer ; Kuek, Vincent ; Zhou, Chi ; Wang, Haibin ; Zou, Xuting ; Hong, Zhinan ; Yang, Fan ; Shao, Min ; Chen, Leilei ; Xu, Jiake. / Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways. In: Journal of Cellular Physiology. 2019 ; Vol. 234, No. 7. pp. 11792-11804.
@article{a194664e6a4a4c2cbde1ecd014baf910,
title = "Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways",
abstract = "Osteoporosis is a form of osteolytic disease caused by an imbalance in bone homeostasis, with reductions in osteoblast bone formation, and augmented osteoclast formation and resorption resulting in reduced bone mass. Cajaninstilbene acid (CSA) is a natural compound derived from pigeon pea leaves. CSA possesses beneficial properties as an anti-inflammatory, antibacterial, antihepatitis, and anticancer agent; however, its potential to modulate bone homeostasis and osteoporosis has not been studied. We observed that CSA has the ability to suppress RANKL-mediated osteoclastogenesis, osteoclast marker gene expression, and bone resorption in a dose-dependent manner. Mechanistically, it was revealed that CSA attenuates RANKL-activated NF-κB and nuclear factor of activated T-cell pathways and inhibited phosphorylation of key signaling mediators c-Fos, V-ATPase-d2, and ERK. Moreover, in osteoclasts, CSA blocked RANKL-induced ROS activity as well as calcium oscillations. We further evaluated the therapeutic effect of CSA in a preclinical mouse model and showed that in vivo treatment of ovariectomized C57BL/6 mice with CSA protects the mice from osteoporotic bone loss. Thus, this study demonstrates that osteolytic bone diseases can potentially be treated by CSA.",
keywords = "bone resorption, CSA, osteoclast, osteoporosis, OVX mice, RANKL",
author = "Y Sun and Yuhao Liu and Wei He and Chao Wang and Jennifer Tickner and Vincent Kuek and Chi Zhou and Haibin Wang and Xuting Zou and Zhinan Hong and Fan Yang and Min Shao and Leilei Chen and Jiake Xu",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/jcp.27868",
language = "English",
volume = "234",
pages = "11792--11804",
journal = "Journal Cellular Physiology",
issn = "0021-9541",
publisher = "John Wiley & Sons",
number = "7",

}

Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways. / Sun, Y; Liu, Yuhao; He, Wei; Wang, Chao; Tickner, Jennifer; Kuek, Vincent; Zhou, Chi; Wang, Haibin; Zou, Xuting; Hong, Zhinan; Yang, Fan; Shao, Min; Chen, Leilei; Xu, Jiake.

In: Journal of Cellular Physiology, Vol. 234, No. 7, 01.07.2019, p. 11792-11804.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cajaninstilbene acid inhibits osteoporosis through suppressing osteoclast formation and RANKL-induced signaling pathways

AU - Sun, Y

AU - Liu, Yuhao

AU - He, Wei

AU - Wang, Chao

AU - Tickner, Jennifer

AU - Kuek, Vincent

AU - Zhou, Chi

AU - Wang, Haibin

AU - Zou, Xuting

AU - Hong, Zhinan

AU - Yang, Fan

AU - Shao, Min

AU - Chen, Leilei

AU - Xu, Jiake

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Osteoporosis is a form of osteolytic disease caused by an imbalance in bone homeostasis, with reductions in osteoblast bone formation, and augmented osteoclast formation and resorption resulting in reduced bone mass. Cajaninstilbene acid (CSA) is a natural compound derived from pigeon pea leaves. CSA possesses beneficial properties as an anti-inflammatory, antibacterial, antihepatitis, and anticancer agent; however, its potential to modulate bone homeostasis and osteoporosis has not been studied. We observed that CSA has the ability to suppress RANKL-mediated osteoclastogenesis, osteoclast marker gene expression, and bone resorption in a dose-dependent manner. Mechanistically, it was revealed that CSA attenuates RANKL-activated NF-κB and nuclear factor of activated T-cell pathways and inhibited phosphorylation of key signaling mediators c-Fos, V-ATPase-d2, and ERK. Moreover, in osteoclasts, CSA blocked RANKL-induced ROS activity as well as calcium oscillations. We further evaluated the therapeutic effect of CSA in a preclinical mouse model and showed that in vivo treatment of ovariectomized C57BL/6 mice with CSA protects the mice from osteoporotic bone loss. Thus, this study demonstrates that osteolytic bone diseases can potentially be treated by CSA.

AB - Osteoporosis is a form of osteolytic disease caused by an imbalance in bone homeostasis, with reductions in osteoblast bone formation, and augmented osteoclast formation and resorption resulting in reduced bone mass. Cajaninstilbene acid (CSA) is a natural compound derived from pigeon pea leaves. CSA possesses beneficial properties as an anti-inflammatory, antibacterial, antihepatitis, and anticancer agent; however, its potential to modulate bone homeostasis and osteoporosis has not been studied. We observed that CSA has the ability to suppress RANKL-mediated osteoclastogenesis, osteoclast marker gene expression, and bone resorption in a dose-dependent manner. Mechanistically, it was revealed that CSA attenuates RANKL-activated NF-κB and nuclear factor of activated T-cell pathways and inhibited phosphorylation of key signaling mediators c-Fos, V-ATPase-d2, and ERK. Moreover, in osteoclasts, CSA blocked RANKL-induced ROS activity as well as calcium oscillations. We further evaluated the therapeutic effect of CSA in a preclinical mouse model and showed that in vivo treatment of ovariectomized C57BL/6 mice with CSA protects the mice from osteoporotic bone loss. Thus, this study demonstrates that osteolytic bone diseases can potentially be treated by CSA.

KW - bone resorption

KW - CSA

KW - osteoclast

KW - osteoporosis

KW - OVX mice

KW - RANKL

UR - http://www.scopus.com/inward/record.url?scp=85057950456&partnerID=8YFLogxK

U2 - 10.1002/jcp.27868

DO - 10.1002/jcp.27868

M3 - Article

VL - 234

SP - 11792

EP - 11804

JO - Journal Cellular Physiology

JF - Journal Cellular Physiology

SN - 0021-9541

IS - 7

ER -